Patents Examined by Kara R McMillian
  • Patent number: 10682342
    Abstract: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: June 16, 2020
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov, Rodolphe Hajj
  • Patent number: 10604473
    Abstract: The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, Metabolic Syndrome, polycystic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 31, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., President and Fellows of Harvard College
    Inventors: Barbara B. Kahn, Mark A. Herman, Alan Saghatelian, Edwin Homan
  • Patent number: 10588879
    Abstract: A method of treating age-related macular degeneration. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: March 17, 2020
    Assignee: Aurin Biotech Inc.
    Inventors: Patrick L. McGeer, Moonhee Lee
  • Patent number: 10588319
    Abstract: Water-based formulations (EW) are provided containing no VOC's or alternatively are low in VOC's for wide area space spray to control mosquitoes, flies, and other public health pests. Application via ULV, these formulations have been observed to provide significantly superior control of pests when compared to competitive adulticides. The present formulations provide exceptional preservation of both droplet density in the spray cloud and droplet size as measured by volume mean diameter (VmD). The present formulations provide superior bio-efficacy as measured by both mortality and knockdown of target organisms. The present formulations provide superior biological control, droplet density, and droplet size when applied at concentrations 20-80× less than competitive formulations.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: March 17, 2020
    Inventors: Robert Britt Baker, Kurt P. Vandock, Gary Gore, Byron Reid
  • Patent number: 10576155
    Abstract: The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: March 3, 2020
    Assignee: SIRNA THEREAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 10568320
    Abstract: The present invention provides novel compositions and methods for using the insect neuromodulator tyramine and/or one or more derivatives thereof delivered to insect populations to control certain aspects of such populations. The amount of tyramine and/or one or more derivatives thereof delivered on a per insect basis is significantly greater than a naturally-occurring amount of tyramine normally found in insects and causes deleterious effects including mortality of certain insect life forms and disruption of the reproductive capacity of others in the population.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: February 25, 2020
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Foresight Science & Technology Inc.
    Inventors: Robert K. Vander Meer, Satya P. Chinta
  • Patent number: 10570161
    Abstract: A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X=C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 25, 2020
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, LEHIGH UNIVERSITY
    Inventors: Jeffrey D. Laskin, Diane E. Heck, Mou-Tuan Huang, Karine Fabio, Carl J. Lacey, Sherri C. Young, Pramod Mohanta, Christophe Guillon, Ned D. Heindel
  • Patent number: 10449174
    Abstract: Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are Candida, Cryptococcus, and Aspergillus given their propensity to cause opportunistic infections in immunocompromised individuals. This disclosure provides a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species of Candida and Cryptococcus. The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5 ?M. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256 ?M.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: October 22, 2019
    Assignee: Purdue Research Foundation
    Inventors: Kwaku Kyei-Baffour, Mohamed Seleem, Mingji Dai, Haroon Taj Mohammad
  • Patent number: 10428387
    Abstract: Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 1, 2019
    Assignee: University of Massachusetts
    Inventors: Michael R. Green, Leyuan Ma
  • Patent number: 10420734
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Grant
    Filed: March 28, 2015
    Date of Patent: September 24, 2019
    Assignee: Duke University
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Patent number: 10420737
    Abstract: A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: September 24, 2019
    Assignee: NATIONAL DEFENSE EDUCATION AND RESEARCH FOUNDATION
    Inventors: Oliver Yao-Pu Hu, Tung-Yuan Shih
  • Patent number: 10383843
    Abstract: A pharmaceutic composition for treating an allergic skin disorder. It has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: August 20, 2019
    Inventor: Liping Yang
  • Patent number: 10364224
    Abstract: The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: July 30, 2019
    Assignee: Purdue Research Foundation
    Inventors: Mohamed Seleem, Mingji Dai, Dexter Cameron Davis, Haroon Taj Mohammad
  • Patent number: 10335412
    Abstract: The present invention relates to adenine which is useful to activate AMP-activated protein kinase (AMPK) and the use of adenine in the prevention or treatment of conditions or disease and thereby prevent or treat conditions or diseases which can be ameliorated by AMPK in a mammal.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: July 2, 2019
    Assignee: ENERGENESIS BIOMEDICAL CO., LTD
    Inventors: Han-Min Chen, Cheng-Yi Kuo, Chun-Fang Huang, Jiun-Tsai Lin
  • Patent number: 10335414
    Abstract: The present invention provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, eg. cancer, benign tumor, etc.). Related materials and methods are also provided herein.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 2, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Vincent Gattone, Bonnie Blazer-Yost
  • Patent number: 10336717
    Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: July 2, 2019
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian McKeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
  • Patent number: 10328053
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 25, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Patent number: 10307485
    Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 4, 2019
    Assignee: Wyeth LLC
    Inventors: David Hugh Giamalva, Gary Bruce Anderson
  • Patent number: 10301304
    Abstract: The present invention relates to a compound useful as a selective inhibitor of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 28, 2019
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Michael John Boyd, Alex Aronov, Hardwin O'Dowd, Jeremy Green
  • Patent number: 10238644
    Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 26, 2019
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Michael T. Nordsiek, Sharon F. Levy, James Hurn-Joung Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon